Annals of Oncology 9:505-509, 1998
© 1998 European Society for Medical Oncology
research-article |
Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer
1Ear, Nose and Throat Diseases and Plastic Surgery Clinic Klinikum Suhl, Suhl, Germany
2Department of Radiotherapy Klinikum Suhl, Suhl, Germany
Correspondence to:J. Büntzel, MD Ear, Nose and Throat Diseases and Plastic Surgery Clinic Klinikum Suhl A. Schweitzer Strasse 2, D-98527 Suhl, Germany
BACKGROUND: Amifostine has reduced toxicities associated with radiation therapy and platinum-based chemotherapy. In a phase II randomized trial, we investigated the ability of amifostine to reduce the toxicity of carboplatin plus radiotherapy (RCT) in patients with head and neck cancer.
PATIENTS AND METHODS: Thirty-nine patients with stage III or IV squamous cell carcinomas of the head and neck received RCT (following surgery or as primary treatment). Radiotherapy was given five days per week with daily fractions of 2 Gy, up to a total dose of 60 Gy in conjunction with carboplatin 70 mg/m2 on days 1 through 5 and days 21 through 26. Eligible patients were randomised to receive RCT alone or preceded by a rapid infusion of amifostine (500 mg) on the days when carboplatin was administered.
RESULTS: Patients receiving amifostine + RCT (n = 25) had significantly reduced mucositis (P = 0.0001) and xerostomia (P = 0.0001) in comparison with patients receiving RCT alone (n; = 14). Additionally, patients receiving amifostine + RCT had significantly less thrombocytopenia (P = 0.001) and leuko-penia (P = 0.001). At 12 months following therapy, 79% of patients receiving amifostine + RCT had no evidence of disease compared with 64% of those receiving RCT alone.
CONCLUSIONS: Amifostine reduces the RCT-induced toxicities in patients with head and neck cancer and has no negative impact on antitumour efficacy.
amifostine, concurrent chemo- and radiation therapy, head and neck cancer, reduced toxicity, selective cytoprotection
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  G. Russo, R. Haddad, M. Posner, and M. Machtay Radiation Treatment Breaks and Ulcerative Mucositis in Head and Neck Cancer Oncologist, August 1, 2008; 13(8): 886 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. R. Kouvaris, V. E. Kouloulias, and L. J. Vlahos Amifostine: The First Selective-Target and Broad-Spectrum Radioprotector Oncologist, June 1, 2007; 12(6): 738 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. I. Rosenthal Established and emerging uses of cytoprotection in head and neck cancer. Arch Otolaryngol Head Neck Surg, February 1, 2006; 132(2): 129 - 130. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Movsas, C. Scott, C. Langer, M. Werner-Wasik, N. Nicolaou, M. Machtay, C. Smith, R. Axelrod, L. Sarna, T. Wasserman, et al. In Reply: J. Clin. Oncol., October 1, 2005; 23(28): 7233 - 7235. [Full Text] [PDF]
|
|
|
|
|
|
S. S. Leong, E. H. Tan, K. W. Fong, E. Wilder-Smith, Y. K. Ong, B. C. Tai, L. Chew, S. H. Lim, J. Wee, K. M. Lee, et al. Randomized Double-Blind Trial of Combined Modality Treatment With or Without Amifostine in Unresectable Stage III Non-Small-Cell Lung Cancer J. Clin. Oncol., May 1, 2003; 21(9): 1767 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Demiral, O. Yerebakan, V. Simsir, and E. Alpsoy Amifostine-induced Toxic Epidermal Necrolysis during Radiotherapy: a Case Report Jpn. J. Clin. Oncol., November 1, 2002; 32(11): 477 - 479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Machtay, D. I. Rosenthal, D. Hershock, H. Jones, S. Williamson, M. J. Greenberg, G. S. Weinstein, V. M. Aviles, A. A. Chalian, and R. S. Weber Organ Preservation Therapy Using Induction Plus Concurrent Chemoradiation for Advanced Resectable Oropharyngeal Carcinoma: A University of Pennsylvania Phase II Trial J. Clin. Oncol., October 1, 2002; 20(19): 3964 - 3971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Schuchter, M. L. Hensley, N. J. Meropol, and E. P. Winer 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., June 15, 2002; 20(12): 2895 - 2903. [Full Text] [PDF]
|
|
|
|
 |
|
 R. A. ORD and R. H. BLANCHAERT JR Current management of oral cancer: A multidisciplinary approach J Am Dent Assoc, November 1, 2001; 132(suppl_1): 19S - 23S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Kostler, M. Hejna, C. Wenzel, and C. C. Zielinski Oral Mucositis Complicating Chemotherapy and/or Radiotherapy: Options for Prevention and Treatment CA Cancer J Clin, September 1, 2001; 51(5): 290 - 315. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Wolden, M. J. Zelefsky, D. H. Kraus, K. E. Rosenzweig, L. M. Chong, A. R. Shaha, H. Zhang, L. B. Harrison, J. P. Shah, and D. G. Pfister Accelerated Concomitant Boost Radiotherapy and Chemotherapy for Advanced Nasopharyngeal Carcinoma J. Clin. Oncol., February 15, 2001; 19(4): 1105 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. M. Brizel, T. H. Wasserman, M. Henke, V. Strnad, V. Rudat, A. Monnier, F. Eschwege, J. Zhang, L. Russell, W. Oster, et al. Phase III Randomized Trial of Amifostine as a Radioprotector in Head and Neck Cancer J. Clin. Oncol., October 19, 2000; 18(19): 3339 - 3345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Hensley, L. M. Schuchter, C. Lindley, N. J. Meropol, G. I. Cohen, G. Broder, W. J. Gradishar, D. M. Green, R. J. Langdon Jr, R. B. Mitchell, et al. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants J. Clin. Oncol., October 1, 1999; 17(10): 3333 - 3355. [Abstract] [Full Text] [PDF]
|
|